2874 related articles for article (PubMed ID: 30605056)
1. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
2. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
5. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.
Shin WS; Di J; Cao Q; Li B; Seidler PM; Murray KA; Bitan G; Jiang L
Alzheimers Res Ther; 2019 Oct; 11(1):86. PubMed ID: 31627745
[TBL] [Abstract][Full Text] [Related]
6. Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in Mice.
Ghosal K; Fan Q; Dawson HN; Pimplikar SW
PLoS One; 2016; 11(7):e0159435. PubMed ID: 27459671
[TBL] [Abstract][Full Text] [Related]
7. Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.
Ryan P; Patel B; Makwana V; Jadhav HR; Kiefel M; Davey A; Reekie TA; Rudrawar S; Kassiou M
ACS Chem Neurosci; 2018 Jul; 9(7):1530-1551. PubMed ID: 29782794
[TBL] [Abstract][Full Text] [Related]
8. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
9. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
[TBL] [Abstract][Full Text] [Related]
10. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
11. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys J; Valverde A; Checler F
J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
[TBL] [Abstract][Full Text] [Related]
12. The Y
Matrone C; Iannuzzi F; Annunziato L
Ageing Res Rev; 2019 Jul; 52():120-128. PubMed ID: 31039414
[TBL] [Abstract][Full Text] [Related]
13. LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent.
Puzzo D; Piacentini R; Fá M; Gulisano W; Li Puma DD; Staniszewski A; Zhang H; Tropea MR; Cocco S; Palmeri A; Fraser P; D'Adamio L; Grassi C; Arancio O
Elife; 2017 Jul; 6():. PubMed ID: 28696204
[TBL] [Abstract][Full Text] [Related]
14. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
Conway KA; Baxter EW; Felsenstein KM; Reitz AB
Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
[TBL] [Abstract][Full Text] [Related]
15. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
Savelieff MG; Lee S; Liu Y; Lim MH
ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
[TBL] [Abstract][Full Text] [Related]
16. A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition.
Sawmiller D; Habib A; Hou H; Mori T; Fan A; Tian J; Zeng J; Giunta B; Sanberg PR; Mattson MP; Tan J
Biol Psychiatry; 2019 Aug; 86(3):208-220. PubMed ID: 31208706
[TBL] [Abstract][Full Text] [Related]
17. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
[TBL] [Abstract][Full Text] [Related]
18. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.
Takahashi RH; Nagao T; Gouras GK
Pathol Int; 2017 Apr; 67(4):185-193. PubMed ID: 28261941
[TBL] [Abstract][Full Text] [Related]
19. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.
Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG
J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661
[TBL] [Abstract][Full Text] [Related]
20. Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease.
Baig AM
ACS Chem Neurosci; 2019 Jan; 10(1):21-24. PubMed ID: 30160095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
